General
Preferred name
OXCARBAZEPINE
Synonyms
GP 47680 ()
GP47680 ()
NSC-758693 ()
KIN-493 ()
Oxcarbamazepine ()
Trileptal ()
Oxtellar Xr ()
GP-47680 ()
SPN-804 ()
Oxcarbazepina ()
Oxcarbazepine-d4 ()
Oxcarbazepine (CRM) ()
P&D ID
PD001213
CAS
28721-07-5
1134188-71-8
Tags
available
prodrug
drug
Approved by
FDA
First approval
2000
Drug indication
Epilepsy
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Oxcarbazepine is an anticonvulsant drug that reduces the incidence of seizures in epilepsies. It works by decreasing abnormal electrical activity in the brain.
DESCRIPTION Oxcarbazepine is an anticonvulsant and antiepileptic drug. (GtoPdb)
DESCRIPTION Oxcarbazepine is a sodium channel blocker[1]. Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines[2]. Anti-cancer and anticonvulsant effects[2][3].
PRICE 31
DESCRIPTION Active metabolite of oxcarbazepine (Cat. No. 3864) (Tocris Bioactive Compound Library)
DESCRIPTION Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures. The opening and closing of sodium channels allows for the propagation of action potentials along neurons - in epilepsy, these action potentials can occur in excess of that required for normal function, and the repetitive and pathological firing of these action potentials leads to seizure activity. (Enamine Bioactive Compounds)
DESCRIPTION Oxcarbazepine (GP 47680) is an Anti-epileptic Agent. The physiologic effect of oxcarbazepine is by means of Decreased Central Nervous System Disorganized Electrical Activity. (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
0
Compound Sets
28
Axon Medchem Screening Library
3308
Cayman Chemical Bioactives
17340
42590
29995
ChEMBL Approved Drugs
CHEMBL1068
ChEMBL Drugs
CHEMBL1068
Drug Repurposing Hub
DrugBank
DB00776
DrugBank Approved Drugs
DB00776
DrugCentral
2017
DrugCentral Approved Drugs
2017
DrugMAP
DM5PU6O
DrugMAP Approved Drugs
DM5PU6O
DrugMatrix
Enamine Bioactive Compounds
EBC-03777
Enamine BioReference Compounds
Guide to Pharmacology
7254
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1068
Mcule NIBR MoA Box Subset
MCULE-9100100302
MedChem Express Bioactive Compound Library
HY-B0114
NCATS Inxight Approved Drugs
VZI5B1W380
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Oxcarbazepine
TargetMol Bioactive Compound Library
T0440
The Spectrum Collection
Tocris Bioactive Compound Library
3864
External IDs
47
Properties
(calculated by RDKit )
Molecular Weight
252.09
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
0
Ring Count
3
Aromatic Ring Count
2
cLogP
2.64
TPSA
63.4
Fraction CSP3
0.07
Chiral centers
0.0
Largest ring
7.0
QED
0.78
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Apoptosis
Sodium Channel
SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A
Anti-convulsant
Primary Target
Voltage-gated Sodium (NaV) Channels
MOA
Blocker
Sodium Channel Blockers
Sodium Channel blocker
Member status
member
Indication
seizures
Therapeutic Class
Anticonvulsants
Pathway
Membrane Transporter/Ion Channel
Source data